Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company specializing in human genetics and personalized products, has announced the U.S. launch of its new MGT Plus methylation test. This launch, in collaboration with U.S. partner 10X Health, expands their joint product pipeline and strengthens their international collaboration in genetic analysis and longevity research.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It plays a critical role in key metabolic pathways, influencing the function and processing of various biological molecules, including vitamins and neurotransmitters. While existing commercial tests analyze only a limited number of relevant genes, MGT Plus covers a total of 27 genes, providing a more comprehensive view of methylation processes across six interconnected biological pathways. These include energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health. This expanded scope offers more precise insights into key biochemical processes, enabling a deeper understanding of methylation-related metabolic pathways.
“With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways in the body, creating new opportunities for more personalized prevention and health strategies. Our close collaboration with our U.S. partner 10X Health underscores our commitment to making scientific innovations accessible internationally and actively advancing personalized approaches to preventive health,” said Dr. Daniel Wallerstorfer, CEO of Novogenia AG.
The global direct-to-consumer testing market is experiencing robust growth. In 2025, the market size had already reached approximately $4.7 billion and is projected to grow to more than $16.0 billion by 2033. The genetic testing sector, which already represents the largest segment with over 40 percent market share, is developing particularly dynamically. North America plays a leading role, accounting for around 50 percent of the global market volume in 2025. This growth is driven by increasing interest in personalized health information, prevention, and individually tailored health services.
The launch of MGT Plus is timely, as consumers and healthcare providers seek more comprehensive genetic insights to guide preventive care. By offering a broader analysis of methylation-related genes, Novogenia aims to support more personalized health strategies. The collaboration with 10X Health is expected to facilitate the distribution of MGT Plus across the U.S., leveraging their established network to reach a wider audience.
This move aligns with Novogenia's strategy to expand its product portfolio internationally and to strengthen its presence in the rapidly growing genetic testing market. The company's focus on scientific innovation and personalized health solutions positions it well to capitalize on the increasing demand for advanced genetic testing services.
